DelistingJun 12, 2026, 05:02 PM
XORTX to Voluntarily Delist Common Shares from TSX Venture Exchange
AI Summary
XORTX Therapeutics Inc. announced its decision to voluntarily delist its common shares from the TSX Venture Exchange (TSXV). This strategic move aims to reduce costs, administrative burdens, and regulatory complexities associated with maintaining a dual listing. The company believes this will optimize financing initiatives and allow greater focus on its XRx-026 program for long-term shareholder value. Shareholders will continue to have full trading access on Nasdaq, and no action is required on their part.
Key Highlights
- XORTX Therapeutics Inc. elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV).
- The decision aims to eliminate duplicative exchange fees, reduce legal and accounting expenses, and minimize regulatory complexity.
- The delisting is intended to optimize company financing initiatives and enable greater management focus on the XRx-026 program.
- All shareholders, including Canadian shareholders, will maintain full trading access on Nasdaq.
- The voluntary delisting was approved by the Company's Board of Directors.
- Shareholder approval was not required as the common shares are listed on an acceptable alternative market (Nasdaq).
- XORTX will continue to be a reporting issuer under applicable securities laws in Alberta, British Columbia, and Ontario.
Price Impact
More from XRTX